You are here
EMEA approve 100mg as recommended starting dose of Sprycel for chronic phase CML
" Bristol-Myers Squibb is pleased about the approval of the 100mg once-daily stating dose of Sprycel for chronic phase patients..... The clinical data on the new starting dose demonstrate improved patient tolerability whilst maintaining efficacy compared to the previous starting dose of 70mg twice daily," said Frank Pasqualone, General Manager, Bristol-Myers Squibb UK.
.... The clinical data on the new starting dose demonstrate improved patient tolerability whilst maintaining efficacy compared to the previous starting dose of 70mg twice daily," said Frank Pasqualone, General Manager, Bristol-Myers Squibb UK.
for the full version of this article click
The updated SPC is now published on the EMEA site
-scroll to section 4.2 for specific mention of the new 100 mg dose
....here